Publication | Closed Access

Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy

UrologyGenitourinary CancerNccn Prostate CancerMedicineCancer ManagementBrachytherapyUnfavorable-intermediate Risk GroupsProstatic DiseaseOncologyRadiation Oncology